Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NVAX – Novavax, Inc.

Novavax, Inc.
NVAX
$8.90
Name : Novavax, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,445,552,640.00
EPSttm : 2.22
finviz dynamic chart for NVAX
Novavax, Inc.
$8.90
3.47%
$0.32

Float Short %

30.21

Margin Of Safety %

Put/Call OI Ratio

0.64

EPS Next Q Diff

-1.04

EPS Last/This Y

3.85

EPS This/Next Y

-2.62

Price

9.22

Target Price

12.5

Analyst Recom

2.62

Performance Q

30.97

Relative Volume

0.67

Beta

2.69

Ticker: NVAX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-08NVAX7.720.730.31325100
2025-09-09NVAX7.970.720.26328824
2025-09-10NVAX7.960.690.04333230
2025-09-11NVAX8.270.690.17335619
2025-09-12NVAX7.990.680.39337444
2025-09-15NVAX8.090.690.32329438
2025-09-16NVAX8.560.690.29338131
2025-09-17NVAX8.390.694380116930070.1393682839466341687
2025-09-18NVAX8.520.680.10355698
2025-09-22NVAX8.860.680.12325597
2025-09-23NVAX8.680.660.18334699
2025-09-24NVAX8.640.660.02335695
2025-09-25NVAX8.350.650.15339036
2025-09-26NVAX8.550.640.08342859
2025-09-29NVAX8.580.640.20336014
2025-09-30NVAX8.670.640.04337743
2025-10-01NVAX9.490.630.10342952
2025-10-02NVAX9.560.630.08347930
2025-10-03NVAX9.450.600.14357313
2025-10-06NVAX9.070.620.98341744
2025-10-07NVAX9.220.640.14349863
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-08NVAX7.7322.5- 2.62
2025-09-09NVAX7.9722.5- 2.62
2025-09-10NVAX7.9522.5- 2.62
2025-09-11NVAX8.2822.5- 2.62
2025-09-12NVAX7.9922.5- 2.62
2025-09-15NVAX8.0922.5- 2.62
2025-09-16NVAX8.5622.5- 2.62
2025-09-17NVAX8.3922.5- 2.62
2025-09-18NVAX8.5222.5- 2.62
2025-09-19NVAX8.7122.5- 2.62
2025-09-22NVAX8.8722.5- 2.62
2025-09-23NVAX8.6822.5- 2.62
2025-09-24NVAX8.6422.5- 2.62
2025-09-25NVAX8.3422.5- 2.62
2025-09-26NVAX8.5522.5- 2.62
2025-09-29NVAX8.5822.5- 2.62
2025-09-30NVAX8.6622.5- 2.62
2025-10-01NVAX9.5022.5- 2.62
2025-10-02NVAX9.4922.5- 2.62
2025-10-03NVAX9.4622.5- 2.62
2025-10-06NVAX9.0822.5- 2.62
2025-10-07NVAX9.2222.5- 2.62
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-08NVAX0.004.3425.75
2025-09-09NVAX0.004.3425.75
2025-09-10NVAX0.004.3425.75
2025-09-11NVAX0.004.3429.65
2025-09-12NVAX0.004.3429.65
2025-09-15NVAX0.004.4229.65
2025-09-16NVAX0.004.4229.65
2025-09-17NVAX0.004.4229.65
2025-09-18NVAX0.004.4229.65
2025-09-19NVAX0.004.4229.65
2025-09-22NVAX0.004.4629.65
2025-09-23NVAX0.004.4629.65
2025-09-24NVAX0.004.4629.65
2025-09-25NVAX0.004.4630.23
2025-09-26NVAX0.004.4630.23
2025-09-29NVAX0.004.4630.21
2025-09-30NVAX0.004.4630.21
2025-10-01NVAX0.004.4630.21
2025-10-02NVAX0.004.4630.21
2025-10-03NVAX0.004.4630.21
2025-10-06NVAX0.002.0330.21
2025-10-07NVAX0.002.0330.21
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

0.62

Avg. EPS Est. Current Quarter

-0.47

Avg. EPS Est. Next Quarter

-0.42

Insider Transactions

Institutional Transactions

2.03

Beta

2.69

Average Sales Estimate Current Quarter

55

Average Sales Estimate Next Quarter

128

Fair Value

Quality Score

98

Growth Score

31

Sentiment Score

41

Actual DrawDown %

97.2

Max Drawdown 5-Year %

-98.8

Target Price

12.5

P/E

4.08

Forward P/E

PEG

0.11

P/S

1.39

P/B

39.74

P/Free Cash Flow

EPS

2.26

Average EPS Est. Cur. Y​

2.62

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

39.2

Relative Volume

0.67

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

0.2

EBIT Estimation

Novavax, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 952
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
stock quote shares NVAX – Novavax, Inc. Stock Price stock today
news today NVAX – Novavax, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NVAX – Novavax, Inc. yahoo finance google finance
stock history NVAX – Novavax, Inc. invest stock market
stock prices NVAX premarket after hours
ticker NVAX fair value insiders trading